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Trypanosoma cruzi infection induces an intense inflammatory response in diverse host 
tissues. The immune response and the microvascular abnormalities associated with 
infection are crucial aspects in the generation of heart damage in Chagas disease. Upon 
parasite uptake, macrophages, which are involved in the clearance of infection, increase 
inflammatory mediators, leading to parasite killing. The exacerbation of the inflammatory 
response may lead to tissue damage. Peroxisome proliferator-activated receptor gamma 
(PPARγ) is a ligand-dependent nuclear transcription factor that exerts important anti- 
inflammatory effects and is involved in improving endothelial functions and proangiogenic 
capacities. In this study, we evaluated the intermolecular interaction between PPARγ and 
a new synthetic PPARγ ligand, HP24, using virtual docking. Also, we showed that early 
treatment with HP24, decreases the expression of NOS2, a pro-inflammatory mediator, 
and stimulates proangiogenic mediators (vascular endothelial growth factor A, CD31, 
and Arginase I) both in macrophages and in the heart of T. cruzi-infected mice. Moreover, 
HP24 reduces the inflammatory response, cardiac fibrosis and the levels of inflammatory 
cytokines (TNF-α, interleukin 6) released by macrophages of T. cruzi-infected mice. 
We consider that PPARγ agonists might be useful as coadjuvants of the antiparasitic 
treatment of Chagas disease, to delay, reverse, or preclude the onset of heart damage.
Keywords: Trypanosoma cruzi, angiogenesis, new peroxisome proliferator-activated receptor gamma agonist, 
macrophages, inflammatory mediators, heart fibrosis
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inTrODUcTiOn
Chagas disease (American trypanosomiasis) is caused by the 
protozoan parasite Trypanosoma cruzi. The acute phase of 
infection is characterized by the presence of parasites in the host 
bloodstream and diverse tissues.
Acute T. cruzi infection is characterized by parasite invasion 
of the heart and other organs. Monocytes that are recruited from 
blood to the heart differentiate into macrophages that mediate 
the control of the parasite load. Macrophages produce pro-
inflammatory mediators in situ, such as nitric oxide (NO), TNF-
α, and interleukin 6 (IL-6), that inhibit T. cruzi multiplication 
and differentiation, precluding the spread of the infection within 
the host (1). In this regard, some studies have shown that mice 
administered iNOS inhibitors exhibit higher parasite levels and 
greater mortality than untreated mice (2, 3). Also, other authors 
have shown the relevant role of TNF-α in protection of mice dur-
ing the acute T. cruzi infection (4–6).
On the other hand, a pro-inflammatory response may pre-
cipitate pathological conditions. In Chagas disease, the antigenic 
stimuli persist for years. The expression of pro-inflammatory 
mediators such as tumor necrosis factor-alpha (TNF-α), IL-6, 
interleukin 1 beta (IL-1β), and nitric oxide synthase 2 (NOS2) 
is associated with progressive tissue damage, leading to cardiac 
pathological conditions (7–11).
The infection-associated immunopathology and microvas-
cular abnormalities are crucial aspects in the generation of 
heart disease, which is characterized by myocytolysis, throm-
boembolism, dysrhythmia, and cardiac hypertrophy (12). The 
progression of the disease is favored by these features, which 
lead to a gradual reduction in coronary flow. In this microen-
vironment M2 macrophages might play a crucial role, because 
they contribute to a range of physiological processes, including 
homeostasis, repair, metabolic functions, and angiogenesis, 
by secreting a plethora of proangiogenic factors like vascular 
endothelial growth factor A (VEGF-A), CD31, NOS3, and other 
cytokines, which increase the proliferation of endothelial and 
epithelial cells to induce neovascularization (13–15).
Peroxisome proliferator-activated receptor gamma (PPARγ) 
is a ligand-dependent transcription factor of the nuclear recep-
tor superfamily, involved in the regulation of lipid metabolism, 
insulin sensitivity, and inflammatory response (16). It has been 
suggested that PPARγ is involved in the molecular mechanisms 
that regulate neoangiogenesis, through the action of growth 
factors and cytokines that stimulate migration, proliferation, 
and survival of endothelial cells (17). PPARγ ligands enhance 
VEGF-A expression in human vascular smooth muscle cells and 
upregulate NOS3 expression in myocardial infarction (18, 19). 
Particularly, it has been demonstrated that troglitazone enhances 
the expression of VEGFR-2 in HUVEC cells through PPARγ 
activation (20). However, some studies have shown that PPARγ 
and PPARα activation inhibits angiogenesis in vitro and in vivo, 
affecting vascular remodeling and leading to reduction of tumor 
cell growth (21). Thus, it is important to undertake studies to 
increase the knowledge about the possible role of PPARγ recep-
tor and its ligands in heart angiogenesis, particularly in Chagas 
disease.
The new PPARγ synthetic ligand 3-hydroxy-4-pyridine-
carboxylic acid derivative 24 (HP24), an aza-analog of salicylic 
acid and structurally close to other potent anti-inflammatory 
pyridine compounds, has been tested in dextran sulfate 
sodium-induced colitis in mice, where it showed a significant 
decrease in colonic myeloperoxidase activity and IL-1β tissue 
levels, exhibiting its anti-inflammatory activity without cyto-
toxic activity (22).
Pharmacological interventions leading to enhanced vascular 
development and reduction of inflammation and fibrosis might 
be useful to prevent heart functional abnormalities. The aim of 
this study was to determine the effect of the new PPARγ ligand 
HP24 in angiogenesis and in the levels of inflammatory media-




The BALB/c mice used in this study were bred and maintained 
in the animal facility at the Instituto de Investigaciones en 
Microbiología y Parasitología Médica (IMPaM), Universidad de 
Buenos Aires–CONICET. All the procedures were approved by 
the Institutional Committee for the Care and Use of Laboratory 
Animals (CICUAL, Facultad de Medicina, Universidad de Buenos 
Aires, CD No. 2271/2014) and are in accordance with the guide-
lines of the Argentinean National Administration of Medicines, 
Food and Medical Technology (ANMAT), Argentinean National 
Service of Sanity and Agrifoods Quality (SENASA) and also 
based on the US NIH Guide for the Care and Use of Laboratory 
Animals.
Mice and infection
All mice were provided with a 12-h day/night cycle and water 
and food ad libitum with a standard diet. Seven male mice per 
group were infected intraperitoneally with 1 × 105 bloodstream 
trypomastigotes of a lethal RA (pantropic/reticulotropic) sub-
population of T. cruzi (23) and sacrificed by CO2 inhalation at 
10 days postinfection (dpi). Each experiment was carried out at 
least three times.
synthesis of 1-Methyl-3-hydroxy- 
4-Pyridinecarboxylic acid  
Derivative 24 (hP24)
1-Methyl-3-hydroxy-4-pyridinecarboxylic acid derivative was 
resynthesized following the previously reported pathway by 
Brun et al. (22) with some modifications in the reaction condi-
tions for the final steps of the synthesis and the purification 
step that led to the desired compound HP24 in the zwitterion 
form (Figure 1A) instead of the previously described chloride 
compound. 3-Hydroxy-isonicotinic acid (1 g, 7.18 mmol) was 
suspended in 5 ml of DMF in a 25-ml round bottomed flask. 
The resulting suspension was stirred at room temperature, 
and 10% NaOH (7.5  ml) was added dropwise until complete 
dissolution of the solid (pH 9–10). Methyl iodide (2.06  g, 
14.46 mmol, d = 2.28 g/ml, 0.9 ml) was added under stirring 
FigUre 1 | HP24 interacts with peroxisome proliferator-activated receptor gamma (PPARγ). (a) Route for HP24 synthesis. (B) Predicted binding mode for HP24 to 
PPARγ. On the right panel, we show rosiglitazone (RSG) from complex crystallographic structure (PDB id 2PRG) superimposed to most probably conformation  
of HP24 compound from docking calculations. RSG, HP24, and receptor binding site amino acids are shown in stick representation, colored by atom type (oxygen, 
nitrogen, sulfur in red, blue, and yellow, respectively) except carbons, which are colored in pink, green, and cyan respectively. Receptor backbone is shown in  
gray with New Ribbon representation. On the left panel, we show chemical formula of RSG and HP24. The images were generated using VMD software (24).  
(c) Peritoneal macrophages from Trypanosoma cruzi-infected mice were preincubated with T0070907 (50 µM), a PPARγ specific antagonist, for 30 min. Then, 
incubated with HP24 (100 µM). After 48 h, nitrite accumulation was measured in the cultured medium. For panel (c), results represent the mean ± SEM of three 
independent experiments (five mice per group). *P < 0.05 vs. uninfected cells, #P < 0.05 vs. T. cruzi-infected cells. ^P < 0.05 vs. T. cruzi-infected HP24-treated cells.
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and the solution was then refluxed, monitoring the reaction 
progress by thin layer chromatography (n-butanol:H2O:AcOH, 
1:1:1). Once the starting material disappeared, the solvent was 
removed under reduced pressure, obtaining a deep orange 
colored solid, which was dissolved in boiling water (50  ml). 
The solution was acidified with 37% HCl (3.5  ml), and 10% 
H2O2 (1  ml) was added. Then, the iodine was exhaustively 
extracted with CHCl3 (5× 15 ml) in a separating funnel. The 
organic phase was concentrated under pressure to dryness, 
obtaining an orange crude raw powdery solid (1.662 g), which 
was purified by reversed-phase chromatography in a Biotage 
Isolera Spektra Flash Chromatography apparatus equipped 
with prepacked C18 cartridges. The fractions containing the 
product were pooled and concentrated to dryness by means of 
a rotary evaporator, yielding a white powdery product (0.956 g, 
6.21 mmol).
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3-Hydroxy-1-Methylpyridin-1-Ium-4-Carboxylate 
(HP24)
Yield: 86.4%; mp: 236°C (decomposition); Rf: 0.13 
(n-butanol:H2O:AcOH, 1:1:1); IR (KBr): ν (cm−1) = 3,432 (OH), 
3,079 (=C–H), 2,850 (CH3), 1,654 (COO−), 1,480 (C=C), 1,381 
(C=N), 1,300 (C–N) cm−1; 1H NMR (300  MHz, [D6] DMSO) 
δ = 8.43 (s, 1H, H-2), 8.01 (d, J = 6.00 Hz, 1H, H-6), 7.98 (d, 
J = 6.03 Hz, 1H, H-5), 4.19 ppm (s, 3H, N-CH3); 13C NMR (75 MHz, 
[D6] DMSO) δ =  47.98 (N-CH3), 126.85 (C-5), 129.73 (C-4), 
130.72 (C-6), 137.54 (C-2), 164.99 (C-3), 166.95 ppm (COO−); 
HRMS (ESI-MS, 140 eV): m/z [M + H+] calculated for C7 8 3H NO+, 
154.0504; found, 154.0545; RT-HPLC, C18: tR = 5.40 min, 97.61 
A%; elemental analyses: calculated for C7H7NO3, C 54.9%, 
H 4.61%, N 9.15%; found: C 54.47%, H 4.39%, N 8.98%.
Treatment of Mice with hP24
Mice were treated by oral gavage with HP24 (400  mg/kg/day) 
suspended in phosphate-buffered saline (PBS), according to 
Brun et  al. (25), for 9 days, since day 1 postinfection (pi), and 
sacrificed at day 10 pi. Euthanasia was carried out at this time 
for humanitarian reasons due to the unhealthy conditions of the 
mice infected with the RA parasite strain.
Parasitemia, Body Weight,  
and survival of Mice
Parasitemia of T. cruzi-infected mice was analyzed through a 
small incision at the end of the tail. Blood from T. cruzi-infected 
mice and T. cruzi-infected HP24-treated mice was obtained at 3, 
5, 8, and 10 dpi. Fivefold dilutions were obtained in red blood cell 
lysis buffer (150 mM NH4Cl, 0.1 mM EDTA, and 10 mM KHCO3, 
pH 7.4). Parasitemia was measured in a Neubauer chamber. 
Body weight gain or loss was monitored on the days descri-
bed previously. For survival studies, two independent groups 
(T. cruzi-infected and T. cruzi-infected HP24-treated mice) of 
seven animals each were followed up daily until different days 
postinfection and analyzed by the Kaplan–Meyer method.
Molecular Modeling
To elucidate the binding mode of the HP24 molecule, docking 
calculations were performed against a murine PPARγ receptor. 
First, we built an homology model with MODELLER software 
(26) using human PPARγ structures as template from Protein 
Data Bank (http://www.pdb.org), PDB id 5DV6 and 2PRG 
(27). Then, we built and optimized HP24 ligand structure with 
Molefacture module of VMD software (24) employing default 
settings for convergence criteria. Finally, AutoDock4 software 
(28) with Water Site Biased Method (29) was used for docking 
experiments. The PPARγ binding site (BS) was defined as all 
atoms within a radius of 10  Å from the co-crystallized ligand 
rosiglitazone (RSG, PDB id 2PRG). The receptor BS amino 
acids were treated as rigid structures during the calculations. 
A total of 100 different docking runs were performed, and the 
results were clustered according to the ligand-heavy atom RMSD 
using a cutoff of 2 Å. The genetic algorithm parameters for each 
conformational search run were kept at their default values. The 
AutoDock4.2 energy function (OA atom type map) was modified 
adding an additional energy term for each crystallographic water 
(CWS) placed on ABS BS in the apo form (PDB id 1PRG) to the 
original function (29).
isolation of Peritoneal Macrophages
Macrophages were obtained by washing the peritoneal cavity of 
mice with 8 ml of RPMI-1640 culture medium (Invitrogen Life 
Technologies, Grand Island, NY, USA), supplemented with 10% 
of heat-inactivated fetal bovine serum (FBS) (Internegocios 
S.A., Argentina) and antibiotics (50  µg/ml of penicillin, 
streptomycin, and gentamicin). Cells were left to adhere to the 
plastic surface of cell culture dishes, 35 mm × 10 mm (Greiner 
Bio One International AG) for 3  h at 37°C under a 5% CO2 
atmosphere (30).
Treatment with hP24 and T0070907 In Vitro
Peritoneal macrophages were isolated from T. cruzi-infected mice 
as indicated above. The cells were preincubated for 30 min with 
specific PPARγ antagonist, T0070907 (50 µM in DMSO) (Sigma-
Aldrich Co., St. Louis, MO, USA), and treated afterward with 
HP24 (100 µM in PBS) for 48 h. Cell viability was examined by 
Trypan Blue dye exclusion test, for each treatment.
Measurement of nO Production by 
Peritoneal Macrophages In Vitro
Release of NO by peritoneal macrophages from T. cruzi-infected 
mice was assessed by the Griess reaction, as previously described 
(31). The absorbance at 540 nm was compared with a standard 
curve of NaNO2.
Macrophage-induced angiogenesis
Macrophage-induced angiogenesis was quantified with an in vivo 
bioassay. After detaching, the concentration of macrophages was 
adjusted to 2 ×  105  cells/ml in culture medium without FBS. 
Seven normal syngeneic male mice per group were inoculated 
intradermally in both flanks with 0.1 ml of cell suspension. Five 
days after inoculation, mice were sacrificed, and the internal layer 
of skin was separated from the underlying tissues, and the vascu-
lar response was observed with a dissecting microscope (Konus 
USA Corporation, Miami, FL, USA) at a 7.5× magnification and 
photographed with an incorporated digital camera (Canon Power 
Shot A45, Canon USA, Inc., Lake Success, NY, USA). Photos were 
projected on a reticular screen to count the number of vessels per 
square millimeters of skin. Angiogenesis was quantified as vessel 
density, calculated as the total number of vessels divided by the 
total number of squares (32).
coculture of Macrophages with heart 
explants
Macrophages (1.5 × 106) from uninfected, T. cruzi-infected and 
T. cruzi-infected HP24-treated mice were obtained and cultured 
with heart slices (100 mg/sample) from uninfected and T. cruzi-
infected mice in 4 ml RPMI-1640 culture medium (Invitrogen 
Life Technologies, Grand Island, NY, USA). After 48 h, the culture 
supernatants were collected, and hearts were homogenized to 
obtain total proteins as previously described (33).
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histopathological studies
Hearts of all experimental groups were fixed in 4% paraform-
aldehyde in PBS, dehydrated and embedded in paraffin. Six 
non-contiguous sections (5 µm) were stained with hematoxylin– 
eosin or Masson trichrome stain. Cellular infiltrates, presence 
of amastigote nests and collagen deposition were examined 
in using a Nikon Eclipse E600 microscope (Nikon Inc.). 
Images were captured with a Spot RT digital camera. At least 
30 random microscopic fields (400×) were analyzed in each 
microscopic section, using the open source Image J software 
(NIH, USA) (34).
Quantitative real-time reverse-
Transcriptase Polymerase chain reaction 
(rT-qPcr)
Total RNA was extracted from frozen cells by using a QuickZol 
reagent (Kalium Technologies, Buenos Aires-Argentina). Total 
RNA was reverse-transcribed using Expand Reverse Trans-
criptase (Invitrogen Corp., MA, USA). RT-qPCR was performed 
using a 5× HOT FIREPol® EvaGreen® qPCR Mix Plus (ROX) 
(Solis BioDyneCorp., Estonia) in an Applied Biosystems 7,500 
sequence detector. Primer sequences were: 18S: Fw 5′AACA 
CGGGAAACCTCACCC 3′, Rv 5′ CCACCAACTAAGAACGGC 
CA 3′; connective tissue growth factor (CTGF): Fw 5′ CCTAAA 
ATCGCCAAGCCTGT 3′, Rv 5′ CACCCCGCAGAACTTAGCC 
3′, and PPARγ: Fw 5′ ATCTACACGATGCTGGC 3′, Rv 5′ 
GGATGTCCTCGATGGG 3′; PCR parameters were 52°C for 
2 min, 95°C for 15 min, and 40 cycles of 95°C for 30 s and 60°C 
(for 18S), 63°C (for CTGF) or 54°C (for PPARγ). Quantification 
was calculated using the comparative threshold cycle (Ct) method 
and the efficiency of the RT reaction ( , ).∆∆relative quantity Ct2−   
The replicates were then averaged, and fold induction was deter-
mined, considering the value at time 0 as 1 (35).
Determination of cytokine levels
TNF-α and IL-6 levels in culture supernatants were quantified by 
enzyme-linked immunosorbent assays using DuoSet antibody 
pairs (R&D Systems, Minneapolis, MN, USA).
Preparation of Total Protein extracts  
for Western Blot
Total protein extracts were obtained after washing the hearts 
with PBS and adding 300  ml of RIPA modified lysis buffer 
(50  mM NaCl, 50  mM Tris–HCl (pH 7.40), 1% Triton X-100, 
1 mM EDTA, 1 mM PMSF; 2.5 g/l Protease Inhibitor Cocktail 
(Sigma-Aldrich Co., St. Louis, MO, USA), 1 mM Na3VO4, 1 mM 
NaF), or washing the cultured cells and scraped off the dishes 
with 50 µl of the same buffer. Then, the tubes were kept on ice 
for 30  min with swirling, and the samples were centrifuged at 
7,000  g at 4°C for 10  min. The supernatants were stored at 
−20°C. Protein concentrations were determined by the Bradford 
method using the Bio-Rad Protein Assay (Bio-Rad, USA) and 
bovine serum albumin (Sigma-Aldrich Co., St. Louis, MO, USA) 
as a standard (36). For Western blot analysis, total proteins were 
boiled in Laemmli sample buffer, and equal amounts of protein 
(40–50 µg) were separated by 10–12% SDS-PAGE. The gels were 
blotted onto a Hybond-P membrane (GE Healthcare, Madrid, 
Spain) and incubated with the following antibodies: anti-NOS2, 
anti-NOS3, anti-Arginase I (Arg-I), anti-CD31, anti-VEGF-A, 
and anti-α-actin (Santa Cruz Biotechnology, CA, USA). The 
blots were revealed by enhanced chemiluminescence in an Image 
Quant 300 cabinet (GE Healthcare Biosciences, PA, USA) follow-
ing the manufacturer’s instructions. Band intensity was analyzed 
using the NIH-ImageJ software (37).
statistical analysis
Data are expressed as the mean of three independent experi-
ments  ±  SEM for each treatment (seven mice/group). The 
Kaplan–Meier test was used to compare survival curves between 
groups. One-way ANOVA was used to analyze the statistical 
significance of the differences observed between the uninfected, 
uninfected HP24-treated, T. cruzi-infected, and T. cruzi-infected 
HP24-treated mice. The Tukey post  hoc test was performed to 
compare all pairs of groups. Kruskal–Wallis test and Dunn’s 
post  hoc test was used to analyze the differences in collagen 
deposition between uninfected, T. cruzi-infected, and T. cruzi-
infected HP24-treated mice. Differences were considered statisti-
cally significant when P <  0.05. All analyses were performed 
using the Prism 5.01 software (GraphPad, USA).
resUlTs
The new Pyridinecarboxylic acid 
Derivative 24 (hP24) interacts with PParγ
Selection of the 3,4-pyridinecarboxylic derivative HP24 was based 
on its properties as PPARγ ligand and on its ability to reduce the 
pro-inflammatory response in a Dextran-induced colitis mouse 
model, as previously reported (22). A simplified synthesis route 
is shown in Figure 1A.
To elucidate how HP24 interacts with PPARγ, we compared 
its binding against that of co-crystallized structure of synthetic 
PPARγ ligand, rosiglitazone (RSG). Figure  1B illustrates the 
superimposition of the best energy docking result for HP24 
(estimated free energy of binding −4.05  kcal/mol), as well as 
the experimental position of the co-crystallized RSG (estimated 
free energy of binding −8.95  kcal/mol), present in the 2PRG 
PDB structure. The most important interaction between RSG 
and PPARγ is a hydrogen bond network with residues GLN286, 
SER289, HIS323, and TYR473. Hydrophobic contacts with 
LEU330, ILE341, MET364, and CYS285 are considered as 
secondary interactions (27). Besides, a detailed visual inspec-
tion of the binding modes for HP24 reveals the same hydrogen 
bond network, adding an extra-polar contact with HIS449 in the 
hydrophilic region of PPARγ BS (Figure 1B, panel right).
Since ligand binding can be inhibited by specific antagonists, 
we designed an in vitro assay to confirm that HP24 binds to PPARγ 
as modeled by the in  silico binding analysis. This involved the 
use of NO release by T. cruzi-infected peritoneal macrophages, 
as an indicator system of the inhibitory effect of HP24 on pro-
inflammatory mediators release. T. cruzi-infected macrophages 
release significantly higher amounts of NO than uninfected 
TaBle 1 | Effect of HP24 on the course of infection.
Parasitemia (× 106) Body weight (g) survival (%)
Day 3 5 8 10 3 5 8 10 3 5 8 10 13
Trypanosoma cruzi – – 1.4 ± 0.32 2.2 ± 0.45 19 ± 0.34 22 ± 0.23 22 ± 0.31 23 ± 0.19 100 100 100 70 10
T. cruzi + HP24 – – 1.3 ± 0.6 2.1 ± 0.27 21 ± 0.5 24 ± 0.48 22 + 0.27 25 ± 0.46 100 100 100 80 15
BALB/c mice were infected by i.p. route with 1 × 105 trypomastigotes of the lethal RA Trypanosoma cruzi strain and treated daily with 400 mg HP24/kg/day. Body weight and 
parasitemia were recorded daily up to day 10 postinfection (p.i.) in each experimental group. Survival was observed daily, up to the end of the experiment (day 13 p.i.) and analyzed 
by the Kaplan–Meyer method. The low number of surviving animals at the end of the study precluded statistical analysis of body weight and parasitemia at this time point. Results 
are expressed as mean ± SEM of three independent experiments (seven mice per group).
FigUre 2 | Peroxisome proliferator-activated receptor gamma (PPARγ) 
expression. PPARγ mRNA expression was analyzed by quantitative real-time 
reverse-transcriptase polymerase chain reaction in peritoneal macrophages 
and heart homogenates from uninfected and Trypanosoma cruzi-infected 
mice, treated or not with HP24. Results were normalized against 18S rRNA. 
Results represent the mean ± SEM of three independent experiments  
(five mice per group). *P < 0.05 vs. uninfected mice.
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macrophages. Moreover, HP24 significantly reduced the release 
of this pro-inflammatory mediator. Notably, preincubation of 
T. cruzi-infected macrophages with the specific PPARγ antago-
nist, T0070907 impeded the effect of HP24 on NO release, thus 
confirming the specific binding and activation of PPARγ by HP24 
(Figure 1C).
As previously reported by our group, infection of mice with 
T. cruzi increases PPARγ expression in the heart and in perito-
neal macrophages (30, 38). In this study, we tested the effect of 
HP24 treatment on PPARγ mRNA levels in macrophages and 
hearts of uninfected and T. cruzi-infected mice. Figure 2 shows 
that HP24 treatment increased the PPARγ mRNA expression 
in uninfected mice, but did not modify the already increased 
expression in T. cruzi-infected mice.
hP24 Treatment Does not affect the 
course of infection
We evaluated whether the treatment with HP24 modified the para-
sitemia levels, weight and survival of T. cruzi-infected mice. These 
parameters were evaluated at 3, 5, 8, 10, and 13 dpi. We found 
no differences in parasitemia levels, weight or survival between 
T. cruzi-infected and T. cruzi-infected HP24-treated mice (Table 1). 
These results are consistent with those previously reported by our 
group with other PPARγ ligands (34).
effect of hP24 on T. cruzi-infected 
Macrophages
We have previously demonstrated that PPARα and PPARγ 
ligands promote the polarization of macrophages isolated from 
T. cruzi-infected mice toward an M2 profile (30).
Here, we evaluated the role of the new PPARγ ligand HP24 
as an anti-inflammatory ligand. We determined its effect on the 
expression of NOS2 and pro-inflammatory cytokines. The treat-
ment with HP24 significantly inhibited NOS2 expression as well as 
TNF-α and IL-6 secretion in macrophages from T. cruzi-infected 
mice (Figure 3A). The PPARγ agonist did not affect the secretion 
of pro-inflammatory cytokines in macrophages from uninfected 
mice (Figure 3A).
We also analyzed whether HP24 was able to promote the 
participation of macrophages in tissue repair and neovascu-
larization processes. To this end, we analyzed the expression of 
representative proangiogenic markers like VEGF-A and Arg-I in 
peritoneal macrophages of T. cruzi-infected mice. Both T. cruzi 
infection and HP24 treatment significantly increased VEGF-A 
expression in peritoneal macrophages with respect to uninfected 
and untreated mice. This effect was potentiated in macrophages 
from T. cruzi-infected HP24-treated mice (Figure 3B). However, 
HP24 was able to significantly increase the expression of Arg-I, 
both in T. cruzi-infected macrophages and in uninfected control 
cells (Figure 3B).
Participation of hP24 in Macrophage-
induced angiogenesis
The formation of new blood vessels requires the sprouting of 
preexisting ones and their subsequent fusion with others (39). 
It has been previously reported that peritoneal macrophages 
from tumor-bearing mice are able to induce a strong neovas-
cular response in the skin of syngeneic normal mice (32). 
Based on these results, we investigated whether HP24 treatment 
modulated the ability of peritoneal macrophages to induce neo-
vascularization in the skin of normal syngeneic mice. Peritoneal 
macrophages from T. cruzi-infected donor mice increased ves-
sel density in comparison with macrophages from uninfected 
donors. Furthermore, macrophages from T. cruzi-infected 
mice-treated in  vitro with HP24 induced a higher increase in 
FigUre 3 | Effect of HP24 on Trypanosoma cruzi-infected macrophages. (a) Nitric oxide synthase 2 (NOS2) expression was determined by Western blot with  
a specific antibody. The release of TNF-α and interleukin 6 (IL-6) to the culture medium was quantitated by capture enzyme-linked immunosorbent assays.  
(B) Peritoneal macrophages were obtained from uninfected, uninfected HP24-treated, T. cruzi-infected, and T. cruzi-infected HP24-treated mice at 10 dpi. Vascular 
endothelial growth factor A (VEGF-A) and Arginase I expressions were determined by Western blot with a specific antibody. Protein levels were normalized against 
α-actin. Results represent the mean ± SEM band intensity of three independent experiments (five mice per group). *P < 0.05 vs. uninfected mice, #P < 0.05 vs.  
T. cruzi-infected mice.
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neovascularization than macrophages from T. cruzi-infected 
donor mice, upon passive transfer in the skin of normal synge-
neic mice (Figure 4A). To assess the participation of PPARγ in 
the effects of macrophage-induced neovascularization, the cells 
were pretreated with the PPARγ antagonist T0070907 and then 
treated with HP24. As shown in Figure 4A the PPARγ antagonist 
reduced the effect of HP24 on new vessel formation in the skin of 
syngeneic normal mice.
Blood vessel density positively correlated with CD31 and 
VEGF-A expression. Western blot analysis showed higher 
expression of CD31 and VEGF-A in skin extracts of normal 
syngeneic recipient mice, upon transfer of macrophages from 
T. cruzi-infected mice treated in  vitro with HP24, than upon 
transfer of macrophages from T. cruzi-infected mice. The PPARγ 
antagonist T0070907 significantly reduced the effects of HP24 
on the expression of CD31 and VEGF-A in the skin of normal 
syngeneic recipient mice upon passive transfer of macrophages 
from T. cruzi-infected mice (Figure 4B).
As expected, CD31 and VEGF-A expression was higher in 
the skin of recipient mice transferred with macrophages from 
T. cruzi-infected mice than in mice transferred with macro-
phages from uninfected controls (Figure 4B).
effect of Macrophages from T. cruzi-
infected hP24-Treated Mice on the 
expression of Proangiogenic Proteins in 
heart explants
To investigate whether macrophages from T. cruzi-infected 
HP24-treated mice participate in heart angiogenesis, we cocul-
tured macrophages from these mice with heart explants from 
T. cruzi-infected mice. Then, we evaluated the expression of 
proangiogenic markers in those explants. Macrophages from 
T. cruzi-infected mice induced an increase in VEGF-A expres-
sion in heart explants, whereas macrophages from control 
mice were unable to modify VEGF-A expression in the same 
explants (Figure 5). When heart explants were cocultured with 
macrophages from T. cruzi-infected mice treated in vitro with 
HP24, the expression of VEGF-A, CD31 and Arg-I was further 
increased (Figure 5).
FigUre 4 | Participation of HP24 in macrophage-induced angiogenesis. (a) Macrophage-induced angiogenesis in mice was determined in vivo by quantification  
of newly formed vessels in the skin. Peritoneal macrophages from different groups were pretreated with the peroxisome proliferator-activated receptor gamma 
antagonist T0070907 and treated with HP24. Then, the cells were harvested and adjusted to 2 × 105 cells/ml. One-tenth milliliters of the cell suspension was 
inoculated by intradermal route in both flanks of syngeneic normal mice. Five days after inoculation, recipient mice were sacrificed, the inner layer of the skin 
exposed, and photographs were acquired. Images were projected on a reticular screen to count the number of vessels per square millimeters. Angiogenesis was 
quantified as the vessel density, calculated as the total number of vessels divided by the total number of squares. (B) CD31 and Vascular endothelial growth factor A 
(VEGF-A) expression were determined by Western blot with a specific antibody. Anti-CD31 and anti-VEGF-A-specific antibody were used. Protein levels were 
normalized against α-actin. Results are mean band intensity ± SEM for three independent experiments (five mice per group). *P < 0.05 vs. uninfected mice 
macrophages, #P < 0.05 vs. Trypanosoma cruzi-infected mice macrophages. ^P < 0.05 vs. HP24-treated macrophages from T. cruzi-infected mice. Mps, 
macrophages.
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Moreover, the effect of HP24 on the expression of VEGF-A, 
CD31 and Arg-I in heart explants was reverted when the mac-
rophages from T. cruzi-infected mice were pretreated with the 
PPARγ antagonist T0070907 (Figure 5).
The same pattern was observed when macrophages were 
cocultured with heart explants from uninfected mice although 
the expression levels were lower (Figure S1 in Supplementary 
Material). Besides, the expression of CD31, VEGF-A and Arg-I 
did not differ in heart explants from T. cruzi-infected mice cul-
tured alone or in the presence of macrophages from uninfected 
control mice (Figure S2 in Supplementary Material).
hP24 Treatment reduces inflammatory 
response and heart Fibrosis in T. cruzi-
infected Mice
We investigated the effects of HP24 treatment on the inflam-
matory response in the heart of T. cruzi-infected mice. Mice 
infected with T. cruzi showed intense inflammatory reaction, 
consisting of mononuclear cell infiltrates. Treatment with 
HP24 significantly reduced heart inflammation (number of 
inflammatory foci/field, T. cruzi vs. T. cruzi-HP24, 0.84 ± 0.41 
vs. 0.21 ±  0.05, N =  5, P <  0.05, Figure  6). We did not find 
FigUre 6 | HP24 reduces heart inflammatory reaction in Trypanosoma 
cruzi-infected mice. Heart inflammatory reaction and parasite nests were 
analyzed at 10 dpi in histological sections of T. cruzi-infected, T. cruzi-infected 
HP24-treated, and uninfected mice, stained with hematoxilin–eosin (bar: 
100 µm, yellow arrows, inflammatory infiltrates, black arrows, amastigote 
nests). Results represent the mean ± SEM of three independent experiments 
(five mice per group). *P < 0.05 vs. uninfected mice, #P < 0.05 vs.  
T. cruzi-infected mice.
FigUre 5 | Effect of Trypanosoma cruzi-infected macrophages from untreated or HP24-treated mice on the expression of proangiogenic proteins in T. cruzi-infected 
heart explants. Peritoneal macrophages were obtained from uninfected and T. cruzi-infected mice at 10 dpi. Macrophages were either pretreated or not with 
T0070907 and then treated with HP24. Then, the cells were cocultured with heart explants (100 mg/sample) from T. cruzi-infected mice. After 48 h, heart explants 
were collected and homogenized. Vascular endothelial growth factor A (VEGF-A), CD31, and Arginase I (Arg-I) expressions were determined by Western blot with 
specific antibodies. Protein levels were normalized against α-actin. Results represent the mean band intensity ± SEM of three independent experiments (five mice 
per group). *P < 0.05 vs. macrophages from uninfected mice + heart explants from T. cruzi-infected mice, #P < 0.05 vs. macrophages from T. cruzi-infected 
mice + heart explants from T. cruzi-infected mice. ^P < 0.05 vs. HP24-treated macrophages from T. cruzi-infected mice + heart explants from T. cruzi-infected  
mice. Mps, macrophages; Tc, T. cruzi.
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significant differences in the number of amastigote nests per 
field between the T. cruzi-infected and T. cruzi-infected HP24-
treated groups (Figure 6).
Fibrosis was observed in heart sections of T. cruzi-infected 
mice using Masson’s trichrome staining (Figure  7A). The 
heart area compromised by collagen deposits was significantly 
reduced in T. cruzi-infected HP24-treated mice (Figure  7B). 
In addition, we analyzed the mRNA expression of CTGF as a 
profibrotic marker. RT-qPCR showed that CTGF expression 
levels were higher in the hearts from T. cruzi-infected mice 
than in those from uninfected mice. Interestingly, treatment 
with HP24 significantly inhibited CTGF mRNA in infected mice 
(Figure 7C).
hP24 Treatment increases the expression 
of Proangiogenic Markers in the heart of 
T. cruzi-infected Mice
To demonstrate the proangiogenic role of the HP24 treatment 
in the hearts of T. cruzi-infected mice, we evaluated the cardiac 
expression of CD31, VEGF-A, NOS3, and Arg-I. Western blot 
analysis showed increased expression of CD31 and VEGF-A in 
hearts upon infection while that of NOS3 and Arg-I remained 
unchanged. Treatment with HP24 promoted the increase of all 
proangiogenic markers in the heart of T. cruzi-infected mice. 
(Figure  8A). Moreover, HP24 treatment in  vivo reduced the 
expression of NOS2 in the hearts of T. cruzi-infected mice in 
comparison with untreated T. cruzi-infected mice (Figure 8B).
DiscUssiOn
In this study, we analyzed the role of the new synthetic PPARγ 
ligand HP24 (22) in cardiac damage and neovascularization, 
in an experimental model of Chagas disease, considering the 
participation of macrophages. We demonstrated that HP24 treat-
ment increased the expression of proangiogenic factors, inhibited 
pro-inflammatory mediators, and reduced fibrosis in the heart 
of infected mice. Moreover, we evidenced that HP24 potentiates 
the ability of macrophages to stimulate angiogenesis in our 
experimental model. PPARγ and its ligands have a wide spectrum 
of functions, regulating metabolism, attenuating inflammation, 
FigUre 7 | Reduction of heart fibrosis by HP24 in Trypanosoma cruzi-infected mice (a).Collagen deposits in heart sections of the experimental groups were  
assessed using Masson’s trichrome (bar: 100 µm). (B) The bar graph shows the percentage of area with fibrosis. (c) Connective tissue growth factor (CTGF)  
mRNA expression was analyzed by quantitative real-time reverse-transcriptase polymerase chain reaction in heart homogenates from all experimental groups. 
Results were normalized against 18S rRNA. All studies were performed at 10 dpi. Results represent the mean ± SEM of three independent experiments  
(five mice per group). *P < 0.05 vs. uninfected mice, #P < 0.05 vs. T. cruzi-infected mice.
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maintaining the balance of immune cells, inhibiting apoptosis 
and oxidative stress, and improving endothelial function (40). 
Results from different experimental models have shown that 
PPARγ and its ligands play a critical role in the regulation of 
various biological processes in the cardiovascular system under 
pathological conditions: they attenuate cardiac fibrosis in diabetic 
rats (41, 42), and alleviate ischemia–reperfusion injury through 
the inhibition of inflammation, improve endothelial function, 
reduce oxidative, stress, and calcium overload in rabbits (43).
Molecular modeling used in this work predicted that the 
main interactions between the PPARγ and HP24 differ little from 
another synthetic agonist, RSG. Our data suggest that HP24 has a 
lower number of non-polar contacts because its volume is lower 
than that of RSG. Only PHE363 and CYS285 are at a suitable 
distance for hydrophobic interaction. In addition, the carbon 
2 of the pyridine ring is at an optimal distance for a possible 
nucleophilic attack by the CYS285. This may be determinant 
for the PPARγ agonist function, since such a covalent bond 
is widely described for the positive regulators of this receptor 
(44, 45). Thus, while the interaction free energy of HP24 with 
PPARγ is higher than that of RSG, the covalent binding that 
might be formed between CYS285 and the pyridine ring of HP24 
would make the binding stable.
To evaluate the implication of PPARγ in HP24 effects, mouse 
peritoneal macrophages were pretreated with the specific PPARγ  
antagonist T0070907 and NO production was evaluated. Rever-
sion of the inhibitory effects of HP24 on the release of NO, together 
with the docking analysis, strongly suggests the binding of HP24 
to PPARγ.
In the present work, we demonstrated that HP24 treatment 
increases VEGF-A expression in macrophages from T. cruzi- 
infected HP24-treated mice. Our results are in agreement with 
those of Kotlinowski et al. (16), who showed that the activation 
of PPARγ by rosiglitazone increases the proangiogenic potential 
of endothelial cells and of bone marrow-derived proangiogenic 
cells (16). In this regard, Biscetti et al. found that the activation of 
PPARγ and PPARα receptors stimulates neoangiogenesis through 
a VEGF-dependent mechanism (17).
We have previously demonstrated that the treatment with 
Wy14643 and 15dPGJ2 (PPARα and PPARγ ligands, respec-
tively) drives peritoneal macrophages toward an M2 profile in 
T. cruzi-infected mice (30). In view of these results, we analyzed 
whether the treatment with HP24 could influence the profiling 
of macrophages. We showed that macrophages from T. cruzi-
infected HP24-treated mice upregulated Arg-I expression and 
downregulated NOS2 expression, processes that strongly suggest 
M2 differentiation. Recently, Assunção et al. demonstrated that 
M2 polarization of macrophages triggered by Schistosomal-
derived lipids occurs through a PPARγ-dependent mechanism 
(46). Interestingly, Odegaard et  al. showed that the promoter 
region of the Arg-I gene has PPARγ response elements (47).
We previously shown that 15dPGJ2 is a potent modulator of 
the inflammatory processes through PPARγ-dependent and - 
independent pathways, in cultures of T. cruzi-infected neonatal 
cardiomyocytes and T. cruzi-infected mice (37, 38). Here, we 
determined the ability of HP24 to exert anti-inflammatory actions 
by inhibiting the expression of a pro-inflammatory enzyme as 
NOS2 and releasing inflammatory cytokines such as TNF-α 
FigUre 8 | HP24 increases the expression of proangiogenic markers and 
decreases nitric oxide synthase 2 (NOS2) in the heart of mice infected with 
Trypanosoma cruzi. Expression of CD31, vascular endothelial growth factor A 
(VEGF-A), NOS3, Arginase I (Arg-I) (a), and NOS2 (B) was determined in the 
heart by Western blot. Anti-CD31, anti-VEGF-A, anti-NOS3, anti-Arg-I, and 
anti-NOS2 specific antibodies were used, and protein levels were normalized 
against α-actin. Results show a representative experiment out of three 
performed. Results represent the mean band intensity ± SEM of three 
independent experiments (five mice per group). *P < 0.05 vs. uninfected 
mice, #P < 0.05 vs. T. cruzi-infected mice.
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and IL-6 in macrophages from T. cruzi-infected mice. In the 
same line of evidence, Brun et al. (22) showed that the synthetic 
PPARγ agonist HP24 improves the outcome of dextran-induced 
colitis, by reducing colonic myeloperoxidase activity and IL-1β 
levels in the gut of mice. These authors also demonstrated that 
HP24 prevents LPS-induced TNF-α and IL-8 release in the same 
model (22).
During acute Chagas disease, oxidative stress associated with 
inflammation of the heart contributes to the tissue damage trig-
gered by T. cruzi infection. This condition stimulates the release 
of a new set of proangiogenic mediators such as VEGF, CD31, 
angiopoietin (Ang)-1 and Ang-2 (48). We cannot discard that 
macrophages participate in this angiogenic process. Regarding 
the latter, our group reported that peritoneal macrophages from 
tumor-bearing mice are able to induce a strong neovascular 
response (32). In this study, we showed that passive transfer 
of macrophages from T. cruzi-infected mice treated in  vitro 
with HP24 enhances angiogenesis, as shown by the increase of 
VEGF-A and CD31 expression in the skin of normal syngeneic 
recipient mice. This effect was dependent on PPARγ signaling, 
since pretreatment of macrophages with the PPARγ antagonist 
precluded the HP24-induced increase of CD31 and VEGF-A in 
skin homogenates of syngeneic normal recipient mice.
Recently, Guedes-da-Silva et  al. (49) showed that antigens 
from the Y strain of T. cruzi are able to promote inflammatory 
neovascularization, probably induced by angiogenic mediators 
produced by macrophages (49). Furthermore, Shrestha et al. (50) 
demonstrated that T. cruzi infection increases the inflammatory 
and angiogenic mediators in the heart of infected mice (50). 
Taking into account that the evolution of Chagas disease is linked 
to microvascular lesions, including obstruction due to throm-
bosis, perivascular inflammation, and lesions in the coronary 
arterioles (33), we believe that the increased neovascularization 
observed during T. cruzi infection may act as a delaying factor 
of the physiopathological mechanisms leading to the cardiac 
symptoms during the course of Chagas disease.
Peritoneal macrophages from T. cruzi-infected mice treated 
in vitro with HP24 induced higher expression of VEGF-A, CD31, 
and Arg-I than macrophages from T. cruzi-infected mice in heart 
explants. As observed in the skin model, these findings suggest 
that HP24 plays a role in inducing macrophages from infected 
mice to promote cardiac angiogenesis. In fact, similarly to what 
was found in the case of passive transfer to the skin, the effect of 
HP24 on the expression of VEGF-A, CD31, and Arg-I depended 
on PPARγ, since pretreatment of macrophages with the PPARγ 
antagonist T0070907 significantly reduced the expression of 
proangiogenic markers in heart explant homogenates. Ashoff 
et  al. demonstrated that treatment of diabetic rats with piogl-
itazone, a synthetic PPARγ agonist, increases the density of 
capillaries in heart and skeletal muscle (51). Besides, de la Torre 
et  al. (33) demonstrated that LPS-treated macrophages from 
septic mice show increased CD31 and VEGF-A expression in 
the heart (33).
However, some studies have shown that PPARγ has antian-
giogenic activity. Pigment epithelial-derived factor and its 
functional peptides inhibit angiogenesis by means of upregula-
tion of PPARγ in a rat model of acute myocardial infarction and 
in an in vitro model of myocardial angiogenesis (52). Funovics 
et  al. (53) and Kim et  al. (54) have shown that PPARγ activa-
tion results in reduced expression of VEGF-R2 and VEGF-R1 in 
endothelial cells (53, 54). These seemingly contradictory findings 
highlight the need for additional studies to determine not only 
the mechanisms through which different PPAR ligands promote 
angiogenesis but also the physiopathological significance of the 
increase of the proangiogenic markers and mediators in the case 
of Chagas disease.
The myocardial infection caused by T. cruzi elicits an intense 
inflammatory response that may act as a “double-edged” sword. 
Although necessary for the control of parasite proliferation, 
inflammation results in tissue damage, leading to myocardial 
fibrosis and remodeling. CTGF, a fibrogenic cytokine, has 
hypertrophic effects, modulating the myocardial phenotype (55). 
In this regard, Koitabashi et al. (56) demonstrated that a dispro-
portionate increase in CTGF expression in cardiac myocytes 
plays a central role in the induction of excessive myocardial 
fibrosis and diastolic heart failure (56). In this study, we showed 
that treatment of T. cruzi-infected mice with HP24 significantly 
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reduces inflammatory response and heart fibrosis, and inhibits 
CTGF expression. We have recently reported that 15dPGJ2, 
a natural PPARγ ligand, is able to reduce the inflammatory 
response, fibrosis, and enzyme markers of liver damage in T. 
cruzi-infected mice (34). It has been shown that activation of 
PPARγ by pioglitazone can attenuate cardiac fibrosis and partly 
ameliorate cardiac remodeling and function by suppressing 
activity of RAS, in a rat model of diabetes (42). Here, we dem-
onstrated that, besides reducing heart fibrosis, HP24 treatment 
induces the expression of proangiogenic markers (VEGF-A, 
CD31, Arg-I, and NOS3) and reduces that of NOS2, in the heart 
of T. cruzi-infected mice.
In conclusion, taking into account that during T. cruzi infection 
microvascular lesions contribute to ischemia and necrosis, the 
early treatment with drugs that reduce inflammation and fibrosis, 
and simultaneously increase microvascular development, might 
be useful as a coadjuvant of the antiparasitic treatment to delay, 
reverse, or preclude the onset of heart damage during the course 
of Chagas disease.
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